Transforming LGMD through Pioneering Gene Therapies

Myonexus Therapeutics is a clinical-stage gene therapy company

Leading Edge

Myonexus Therapeutics in the News

Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies 150 150 Myonexus Therapeutics

Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies

MYO-101 Phase 1/2a systemic gene therapy trial for LGMD2E to begin in early 2018 NEW ALBANY, Ohio–(BUSINESS WIRE)–Myonexus Therapeutics, Inc. (Myonexus), a clinical-stage biotechnology company…

read more
Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies 150 150 Myonexus Therapeutics

Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies

Innovative Gene Therapies with Potential to Become First-ever, Standard of Care Therapies for Limb-Girdle Muscular Dystrophies Announces Management Team of Industry Leaders with Technical and…

read more


Our Mission

Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective gene therapies for Limb-Girdle muscular dystrophies, debilitating rare diseases with no treatments.  

Positively Transforming Lives

Myonexus Therapeutics is developing first ever gene treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C.